The University of Chile announced that by the end of 2022 they hope to finish a vaccine production plant in Chile, in alliance with the Italian pharmaceutical company Reithera. This initiative is in addition to the two plants of the Sinovac laboratory that will be installed on national soil.
The Ministry of Health reported that in the last 24 hours it received the result of 60,081 tests, between PCR and antigens, detecting 515 new coronavirus infections and reaching a positivity of 0.87% nationwide.
They also reported 2,996 active cases, and the Department of Health Statistics and Information, DEIS, reported 37 deaths from causes attributed to the pandemic.
The infectologist at the Hospital del Trabajador, Guillermo Acuña -as has been the trend in recent weeks- highlighted the current health situation, but calling to respect health care measures.
In this regard, the expert highlighted the beginning of vaccination to minors with comorbidities from the age of 6 during the next week, emphasizing it as a great step.
From the next one, it will start with the vaccination process to minors between the ages of 6 and 11 with comorbidities and the vaccination of adolescents between the ages of 14 and 17 will continue.
As explained by the Ministry of Health, after the celebrations of National Holidays, the vaccination process in minors will continue, and there will be included adolescents of 12 and 13 years.
Vaccine production plant
In this context, the rector of the University of Chile, Ennio Vivaldi, referred to the project to build a biotechnology and vaccine production center to combat the pandemic, in partnership with the Italian pharmaceutical company ReiThera.
The academic indicated that they expect to finish the works by the end of 2022, where they hope to begin with the production of up to 100 million doses per year.
The coordinator of the Italian Delegation and Director of Business and Regional Operations of Rosiglioni Impianti, Valerio Branchi, He pointed to the advantages of Chile producing vaccines again.
The Reithera laboratory vaccine is not yet approved by the Institute of Public Health (ISP), however, it delivered an immune response of 99% in phase 2 of its development, and according to the experts, they hope to be approved by the end of the year in Chile, with a main function of booster doses.
Note that this project is added to the 2 plants that are in process by the Chinese laboratory Sinovac.
– .
